Aberdeen Group
LEGN icon

Aberdeen Group’s Legend Biotech LEGN Stock Holding History

Aberdeen Group’s Portfolio LEGN Stock Details LEGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$884K Buy
30,608
+953
+3% +$25.7K ﹤0.01% 840
2026
Q1 		$536K Sell
29,655
-127
-0.4% -$2.42K ﹤0.01% 875
2025
Q4 		$647K Buy
29,782
+11,456
+63% +$328K ﹤0.01% 864
2025
Q3 		$598K Buy
18,326
+4,178
+30% +$154K ﹤0.01% 880
2025
Q2 		$502K Sell
14,148
-638
-4% -$20.7K ﹤0.01% 883
2025
Q1 		$502K Sell
14,786
-16,732
-53% -$600K ﹤0.01% 872
2024
Q4 		$1.03M Sell
31,518
-2,211
-7% -$91.6K ﹤0.01% 821
2024
Q3 		$1.63M Buy
33,729
+17,696
+110% +$943K ﹤0.01% 770
2024
Q2 		$710K Buy
16,033
+2,464
+18% +$114K ﹤0.01% 837
2024
Q1 		$761K Sell
13,569
-2,132
-14% -$129K ﹤0.01% 842
2023
Q4 		$945K Buy
15,701
+2,441
+18% +$155K ﹤0.01% 841
2023
Q3 		$891K Sell
13,260
-2,343
-15% -$163K ﹤0.01% 769
2023
Q2 		$1.08M Buy
15,603
+2,702
+21% +$177K ﹤0.01% 787
2023
Q1 		$622K Sell
12,901
-664
-5% -$32.5K ﹤0.01% 823
2022
Q4 		$677K Buy
13,565
+3,990
+42% +$193K ﹤0.01% 809
2022
Q3 		$391K Buy
9,575
+4,222
+79% +$198K ﹤0.01% 863
2022
Q2 		$295K Buy
+5,353
New +$226K ﹤0.01% 909

Other funds holding LEGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

Aberdeen Group's LEGN Position: Q2 2026 in Review

Aberdeen Group increased its Legend Biotech (LEGN) stake by 3.2% in Q2 2026, buying an estimated $25.7K and bringing the position to 30,608 shares worth $884K. The position accounts for ﹤0.01% of the portfolio, ranked #840.

Aberdeen Group first reported a position in LEGN in Q2 2022 and has held it in 17 quarters since. The position peaked at $1.63M in Q3 2024. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

  • Aberdeen Group held 30,608 shares of Legend Biotech worth $884K as of Q2 2026.
  • Aberdeen Group bought 953 Legend Biotech shares in Q2 2026, an estimated $25.7K.
  • Legend Biotech made up ﹤0.01% of Aberdeen Group's portfolio in Q2 2026, its #840 holding.
  • Aberdeen Group first reported a position in Legend Biotech in Q2 2022 and has held it in 17 quarters since.
  • Aberdeen Group's Legend Biotech position peaked at $1.63M in Q3 2024.
  • 219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.